Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 juil. 2024 13h05 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
30 mai 2024 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
15 mai 2024 16h20 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
15 mai 2024 16h01 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
26 avr. 2024 08h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
24 avr. 2024 16h05 HE
|
Cidara Therapeutics, Inc.
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b...
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
24 avr. 2024 16h01 HE
|
Cidara Therapeutics, Inc.
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an...
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
22 avr. 2024 17h10 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
22 avr. 2024 17h06 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...
Cidara Therapeutics Announces Reverse Stock Split
22 avr. 2024 08h49 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...